Nano-X Imaging Ltd. (NNOX) is an innovative med-tech company that is revolutionizing the global healthcare industry. The company, based in Israel, was co-founded in 2016 by Ran Poliakine, a well-known entrepreneur and technology innovator who has led multiple successful ventures in a variety of technological fields.
At the heart of Nano-X Imaging's industrial pursuit is the objective to make medical imaging widely accessible and affordable for all communities around the world. NNOX aims to tackle two prevalent issues in the medical field - scarcity of medical imaging systems in many parts of the world and the high costs associated with traditional imaging devices.
Nano-X Imaging has developed an advanced digital X-ray technology known as the Nanox System. This system includes two cutting-edge components, the Nanox.Arc and Nanox.Cloud. The Nanox.Arc is a novel medical imaging device that operates using a silicon-based, cold cathode field emission technology that significantly reduces the cost of imaging hardware. The Nanox.Cloud is a companion cloud-based software that provides an array of services including image storage, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting.
The company's innovative technology is intended to transform the way medical imaging services are provided. This will not only increase the patient population's access to these crucial services but also democratize the availability of early-detection services, which can lead to significantly improved health outcomes and save lives.
In 2021, the U.S. Food and Drug Administration (FDA) cleared the company's single-source digital X-ray technology, validating the Nanox System's potential to disrupt the medical imaging industry.
Despite being a relatively young company, Nano-X Imaging has already attracted significant attention and investment. It went public on the NASDAQ in August 2020, seeing a promising surge in its stock value. However, it is not without its challenges as other, more established image technology companies pose strong competition.
Yet, with its innovative technology, veteran leadership, and clear vision, Nano-X Imaging Ltd. (NNOX) has the potential to create paradigm shifts in the healthcare sector, transforming it into a more affordable and accessible service.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Nano-X Imaging (NNOX) has signed a distribution agreement with SOLME RC, S.A. for Costa Rica to market and support its Nanox.ARC system, which is designed to expand access to 3D medical imaging. SOLME will manage marketing, distribution, installation, training, and technical support. This agreement marks Costa Rica as Nanox's third Latin American market this year, following Argentina and Peru, with commercialization subject to regulatory registration including a six-month proof-of-concept period.
Nano-X Imaging (NNOX) announced it will report its financial results for the second quarter of 2026 before market open on September 9, 2026. CEO Erez Meltzer and CFO Guy Nathanzon will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. A live webcast will also be available on the company's investor relations website.
Nano-X Imaging (NASDAQ: NNOX) will report its second-quarter 2026 financial results on September 9, 2026, before market open. CEO Erez Meltzer and CFO Guy Nathanzon will host a conference call and live webcast to discuss the results and provide a business update. The company specializes in medical imaging technology, aiming to transition to preventive healthcare through an integrated platform.
The Gross Law Firm has issued a shareholder alert for Nano-X Imaging Ltd. (NASDAQ: NNOX), announcing a securities class action lawsuit. The lawsuit alleges that Nano-X Imaging Ltd. made materially false or misleading statements regarding its operational efficiency, product demand, and increased operating expenses, leading to artificial inflation of its stock. Investors who purchased NNOX shares between March 31, 2025, and April 17, 2026, are encouraged to contact the firm, with a lead plaintiff deadline of August 11, 2026.
Pomerantz LLP is investigating potential securities fraud claims against Nano-X Imaging Ltd. (NNOX) on behalf of its investors. This investigation follows Nano-X's announcement of a $33.4 million net loss for Q4 2025, primarily due to a $17.5 million impairment charge related to a restructuring at its Korean chip manufacturing facility. Additionally, the company announced that its CFO would be stepping down, leading to a 24.39% drop in Nano-X's stock price.